 |
The World Health Organization and International Clinical Classification recently released an updated classification of Hematolymphoid Malignancies that included the addition of many new molecular and cytogenetic abnormalities. Conventional cytogenetic analysis (karyotyping) has been the primary tool for the detection of structural genome abnormalities. However, many important diagnostic and prognostic abnormalities are below the resolution of karyotpying. To meet the challenges of structural abnormality detection The Cancer Cytogenetics Laboratory at the University Health Network in Toronto has been evaluating optical genome mapping as a replacement for first-line testing in various hematologic malignancies. This Bionano webinar, our distinguished presenter, Dr. Adam Smith, will describe how his organization has evaluated optical genome mapping as a first-line test for hematologic malignancies specifically focusing on acute myeloid leukemia and replacing a legacy eosinophilic leukemia FISH panel. |
